The surprisingly large and irregular practices of the private tuberculosis (TB) drug market could be driving treatment failures and the emergence of multi-drug resistance (MDR), according to a new report in the journal PLoS ONE. The study found the private TB drug market is now just as big as the public market, whereas previously TB […]
HIV
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
Tuberculosis
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
Research & Development
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
With a report showing that 2018 yielded the highest case numbers seen so far of a paralyzing condition largely among children who had been sick with […]